Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LARP4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LARP4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LARP4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LARP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457272 | Colorectum | MSS | positive regulation of translation | 43/3467 | 136/18723 | 1.60e-04 | 2.29e-03 | 43 |
GO:00482551 | Colorectum | MSS | mRNA stabilization | 21/3467 | 56/18723 | 6.51e-04 | 7.06e-03 | 21 |
GO:0070935 | Colorectum | MSS | 3'-UTR-mediated mRNA stabilization | 10/3467 | 24/18723 | 7.25e-03 | 4.63e-02 | 10 |
GO:19033114 | Colorectum | FAP | regulation of mRNA metabolic process | 97/2622 | 288/18723 | 1.35e-17 | 4.13e-14 | 97 |
GO:00098954 | Colorectum | FAP | negative regulation of catabolic process | 91/2622 | 320/18723 | 9.66e-12 | 4.96e-09 | 91 |
GO:00313304 | Colorectum | FAP | negative regulation of cellular catabolic process | 77/2622 | 262/18723 | 6.79e-11 | 2.31e-08 | 77 |
GO:00610134 | Colorectum | FAP | regulation of mRNA catabolic process | 54/2622 | 166/18723 | 8.64e-10 | 1.96e-07 | 54 |
GO:00064024 | Colorectum | FAP | mRNA catabolic process | 68/2622 | 232/18723 | 9.87e-10 | 2.16e-07 | 68 |
GO:00064014 | Colorectum | FAP | RNA catabolic process | 77/2622 | 278/18723 | 1.42e-09 | 2.77e-07 | 77 |
GO:00434874 | Colorectum | FAP | regulation of RNA stability | 53/2622 | 170/18723 | 6.61e-09 | 1.00e-06 | 53 |
GO:00064174 | Colorectum | FAP | regulation of translation | 111/2622 | 468/18723 | 8.47e-09 | 1.13e-06 | 111 |
GO:00434884 | Colorectum | FAP | regulation of mRNA stability | 50/2622 | 158/18723 | 1.01e-08 | 1.27e-06 | 50 |
GO:00442704 | Colorectum | FAP | cellular nitrogen compound catabolic process | 101/2622 | 451/18723 | 7.42e-07 | 3.44e-05 | 101 |
GO:00346554 | Colorectum | FAP | nucleobase-containing compound catabolic process | 92/2622 | 407/18723 | 1.50e-06 | 6.49e-05 | 92 |
GO:00467004 | Colorectum | FAP | heterocycle catabolic process | 98/2622 | 445/18723 | 2.36e-06 | 9.21e-05 | 98 |
GO:00194394 | Colorectum | FAP | aromatic compound catabolic process | 100/2622 | 467/18723 | 6.75e-06 | 2.08e-04 | 100 |
GO:19033124 | Colorectum | FAP | negative regulation of mRNA metabolic process | 29/2622 | 92/18723 | 1.31e-05 | 3.53e-04 | 29 |
GO:19023693 | Colorectum | FAP | negative regulation of RNA catabolic process | 25/2622 | 75/18723 | 1.74e-05 | 4.42e-04 | 25 |
GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
GO:00434893 | Colorectum | FAP | RNA stabilization | 21/2622 | 65/18723 | 1.33e-04 | 2.13e-03 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP4 | SNV | Missense_Mutation | | c.236N>G | p.Ser79Cys | p.S79C | Q71RC2 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LARP4 | SNV | Missense_Mutation | novel | c.1235N>T | p.Arg412Ile | p.R412I | Q71RC2 | protein_coding | tolerated(0.09) | possibly_damaging(0.533) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | novel | c.1484N>T | p.Gly495Val | p.G495V | Q71RC2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | novel | c.1427N>T | p.Ser476Leu | p.S476L | Q71RC2 | protein_coding | tolerated(0.1) | benign(0.007) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
LARP4 | deletion | Frame_Shift_Del | novel | c.954_966delNNNNNNNNNNNNN | p.Pro319ThrfsTer32 | p.P319Tfs*32 | Q71RC2 | protein_coding | | | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
LARP4 | SNV | Missense_Mutation | novel | c.1652N>A | p.Ser551Asn | p.S551N | Q71RC2 | protein_coding | tolerated(0.11) | benign(0.101) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LARP4 | SNV | Missense_Mutation | novel | c.149N>T | p.Ser50Leu | p.S50L | Q71RC2 | protein_coding | tolerated(0.22) | benign(0.006) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
LARP4 | SNV | Missense_Mutation | | c.1463C>T | p.Ser488Leu | p.S488L | Q71RC2 | protein_coding | deleterious(0) | possibly_damaging(0.544) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LARP4 | SNV | Missense_Mutation | | c.1918C>A | p.Leu640Ile | p.L640I | Q71RC2 | protein_coding | tolerated(0.15) | benign(0.091) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LARP4 | SNV | Missense_Mutation | novel | c.1657N>T | p.Pro553Ser | p.P553S | Q71RC2 | protein_coding | tolerated(0.2) | benign(0.006) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |